Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 31Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 22Esophageal Neoplasms 20Esophageal Squamous Cell Carcinoma 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Liver Neoplasms 6Hodgkin Disease 6Cholangiocarcinoma 6Biliary Tract Neoplasms 5Advanced Gastric Cancer 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Solid Tumor 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3

Interventions

Temozolomide 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclophosphamide 2venetoclax 1trametinib 1toripalimab 1tafasitamab 1sonidegib 1ribociclib 1fludarabine 1etoposide phosphate 1camrelizumab 1brivanib 1apatinib 1acalabrutinib 1Vincristine 1Valganciclovir 1Thiotepa 1Therapeutics 1Telemedicine 1Tamoxifen 1Surveys and Questionnaires 1Standard of Care 1Rituximab 1Radiotherapy 1R-CHOP protocol 1Patient Navigation 1N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pyloric Stenosis, Hypertrophic × camrelizumab × Clear all
NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Sun Yat-sen University

Phase 1/2 Unknown
33 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡